Ad
related to: nitroglycerin effects on humans treatment chart printable version
Search results
Results From The WOW.Com Content Network
Three different forms of nitroglycerin: intravenous, sublingual spray, and the nitroglycerin patch. Nitroglycerin is used for the treatment of angina, acute myocardial infarction, severe hypertension, and acute coronary artery spasms. [1] [12] It may be administered intravenously, as a sublingual spray, or as a patch applied to the skin.
The nitrates are used for the treatment and prevention of angina and acute myocardial infarction, while molsidomine acts too slowly to be useful for the treatment of acute angina. [2] For quick action in the treatment of angina, glyceryl trinitrate is used in form of a sublingual spray (nitro spray) or as soft capsules to be crunched.
Nitroglycerin (NG) (alternative spelling of nitroglycerine), also known as trinitroglycerol (TNG), nitro, glyceryl trinitrate (GTN), or 1,2,3-trinitroxypropane, is a dense, colorless or pale yellow, oily, explosive liquid most commonly produced by nitrating glycerol with white fuming nitric acid under conditions appropriate to the formation of the nitric acid ester.
William Murrell (1853–1912) was an English physician, clinical pharmacologist, and toxicologist. Murrell is best known for being one of the first to recognize the clinical benefits of glyceryl trinitrate (also known as nitroglycerin) for the management of patients with angina pectoris.
In mammals including humans, nitric oxide is a signaling molecule involved in several physiological and pathological processes. [1] It is a powerful vasodilator with a half-life of a few seconds in the blood. Standard pharmaceuticals such as nitroglycerine and amyl nitrite are precursors to nitric oxide.
One strategy to avoid this is to schedule nitroglycerin-free periods of between 12 and 14 hours between doses of long-acting nitroglycerin formulations. [17] Individuals whose symptoms are poorly controlled by a calcium blocker may benefit from addition of a long-acting nitroglycerin and/or a second calcium channel blocker of a different class ...
Phosphodiesterase-5. A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
2 O emissions are from humans and the rest are part of the natural nitrogen cycle. [62] The N 2 O emitted each year by humans has a greenhouse effect equivalent to about 3 billion tonnes of carbon dioxide: for comparison humans emitted 37 billion tonnes of actual carbon dioxide in 2019, and methane equivalent to 9 billion tonnes of carbon ...